Skip to main content
Premium Trial:

Request an Annual Quote

Investment Firm to Buy 49 Percent Stake in Olink

NEW YORK (GenomeWeb News) – Nxt2b has signed an agreement to purchase 49 percent of all outstanding shares of Swedish protein and molecular technologies firm Olink Bioscience for an undisclosed amount.

The deal is expected to "accelerate the growth and value creation of the company by injecting knowledge, experience, and financial strength to complement Olink's unique product and technology position," Olink said in a statement.

"Together with Nxt2b, we have now created a foundation to take Olink to new levels of commercial success by combining our unique portfolio of technologies and products with the experience and financial strength of Nxt2b," Olink President and CEO Björn Ekström said.

Nxt2b is a privately owned investment company owned by Bengt Ågerup that focuses on equity investments in medical devices, specialty pharmaceutical companies, and technology and consumer firms.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.